title: [Endocrine therapy of stage D2 prostate cancer--comparison of drugs used for total androgen blockade].
abstract: Patients with Stage D2 prostate cancer were treated with surgical or medical (LHRH analog) castration combined with either estrogen, chlormadinone acetate or flutamide as initial therapy. The effect of each medication was compared. The overall survival, cause-specific survival and relapse-free survival were not different among the three medications. Patients given each medication were divided into two groups each according to grade, extent of diseases on bone metastases, and levels of tumor marker. Survivals of the corresponding two groups were compared with each other among different medications. No differences were revealed with any medication. There were no serious side effects in whole patients, except that grade 2 liver dysfunction was accompanied in 12% of flutamide-treated group. It is concluded that the three drugs used with castration did not make any difference in the survival of stage D2 patients, and differences between medications were seen in the frequency of side effects.
authors.affiliation: Department of Urology, Asahi General Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: N
authors.initials: N
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Hamano
authors.forename: H
authors.initials: H
authors.lastname: Kinsui
authors.forename: T
authors.initials: T
authors.lastname: Oikawa
authors.forename: J
authors.initials: J
authors.lastname: Shimazaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002369:Castration; D002715:Chlormadinone Acetate / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D017329:Triptorelin Pamoate / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D017329:Triptorelin Pamoate; D002715:Chlormadinone Acetate; D005485:Flutamide